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Abstract 
Background: Prophylaxis of vitamin K deficiency bleeding (VKDB) is achieved with 
administration of intramuscular (IM) injection or oral vitamin K (VK) in newborns.   
Objectives: The aim of this study was to compare maternal and infant characteristics by mode of 
VK administration.  
Methods: De-identified computerised birth files of all babies born in NSW, Australia between 
Jan. 2007 and Dec. 2009 (when VK prophylaxis was measured) were included in the present 
study.  The outcome variable, mode of VK prophylaxis, was recorded by checkbox as oral, IM 
injection, none or not stated. 
Results: We analysed population-based birth data from 2007-2009 in NSW, Australia and found 
IM injection was the most prevalent mode of administration (96.3%, n=263, 555), followed by 
oral (2.6%, n=7,023) and none (1.2%, n=3,136). Compared to neonates receiving IM VK, those 
with oral or none were more likely to have vaginal births without medical interventions at birth 
centers or planned homebirths and were less likely to receive hepatitis B vaccination. Preterm 
births and those breast-fed at discharge were more likely to have oral VK compared to IM 
injection.  Neonates with no VK recorded were more likely to be admitted to neonatal intensive 
care, but may have received VK later in the birth admission.   
Conclusions: A small proportion of the Australian neonates may be at risk of inadequate 
protection from VKBD due to parental safety about the safety of IM injection of VK to neonates. 
Keywords: vitamin K; vitamin K deficiency disorder (VKBD); neonate; prophylaxis; 
population-based study 
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What is already known on this topic? 
1. In the 1990’s, UK studies reported an association between intramuscular (IM) injection  
but not oral vitamin K (VK) administration and childhood cancer, particularly leukaemia. 
2. Countries responded in different ways, some moved towards a uniform policy of oral 
prophylaxis (certain European countries), some used a variety of regimens based on 
clinician and hospital-based practices (UK) and some made an initial change to universal 
oral prophylaxis and then later reverted to IM injection prophylaxis (Australia. New 
Zealand). 
3. There is little evidence on parental characteristics and choice of various modes of VK 
prophylaxis administration.   
 
What this paper adds? 
1. This is the first study to examine maternal and infant characteristics by mode of VK 
prophylaxis.  
2. Parental decision to use oral or no VK prophlaxis is aligned with attitudes and 
preferences for a natural birth without medical interventions, suggesting that IM 
prophylaxis of VK is unattractive to parents with concerns about the “medicalisation” of 
birth and the risks of the injection itself. 
3. A small proportion of the Australian neonates may be at risk of inadequate protection 
from VKBD due to parental safety about the safety of IM injection of VK to neonates. 
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Introduction 
From the 1960’s to late 1980’s, intramuscular (IM) injection  of vitamin K (VK) 
prophylaxis to neonates was the route universally adopted in many industrialised countries to 
prevent VK deficiency bleeding (VKDB), a rare and potentially life-threatening bleeding 
disorder in early infancy.1  In the 1990’s, UK studies reported an association between IM but not 
oral VK administration and childhood cancer, particularly leukaemia.2, 3   Countries responded in 
different ways; several European countries moved towards a uniform policy of oral prophylaxis.1   
In the UK, regimens became varied, with numerous permutations of preparation used, route of 
administration, dose, and number of doses.1   In Australia and New Zealand, an initial change to 
universal oral prophylaxis was later reverted to IM injection prophylaxis after cases of late 
VKBD reappeared, attributed to poor efficacy and/or compliance of oral VK.4, 5  Australia 
continues to exercise caution, recommending IM injection of VK as the preferred route and 
providing oral prophylaxis of three doses given at birth, at 3-5 days of age, and in the fourth 
week of life as an alternative option for parents.4   
There is little evidence on parental characteristics and choice of various modes of VK 
prophylaxis administration.  Only one study examining health beliefs associated with low uptake 
of the measles, mumps and rubella (MMR) vaccine in the UK, also examined VK prophylaxis.6  
The investigators found that non-compliance with MMR vaccination was strongly associated 
with the use of complementary healthcare and rejection of VK prophylaxis.6  Therefore, the 
purpose of this study is to compare maternal and infant characteristics by route of VK 
prophylaxis (IM injection compared to oral or none). 
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Methods 
The New South Wales (NSW) Midwives Data Collection (MDC) is a legislated 
population-based surveillance system, which includes information on all babies born at ≥20 
weeks’ gestation or weighing at least 400 g.  De-identified computerised birth files of all babies 
born in NSW, Australia between Jan. 2007 and Dec. 2009 (when VK prophylaxis was measured) 
were included in the present study.  The outcome variable, mode of VK prophylaxis, was 
recorded by checkbox as oral, IM injection, none or not stated. Data for VK prophylaxis as 
"none" only included babies who had VK recorded as "none." Babies for whom the data field 
was left blank (n=232) were excluded from the analysis. 
Explanatory variables included a range of maternal (i.e. age, parity, any medical 
conditions, mode and place of delivery) and infant characteristics (i.e. neonatal hepatitis B 
vaccination, preterm birth, admission to neonatal or special care unit). Analysis was based on 
mothers, therefore for multiple births only the first twin or triplet was used. Infant characteristics 
are recorded soon after birth and do not always include subsequent management of the infant in a 
neonatal or special care unit.  
Multinomial logit analysis was used to examine the association between explanatory 
factors and the odds of neonates having oral and no VK prophylaxis compared to IM injection.   
Analyses were conducted using SAS, version 9.2 (SAS Institute, Cary, NC, USA).  The study 
received ethics approval from the NSW Population and Health Service Research Ethics 
Committee, Australia.   
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Results 
From Jan. 2007 to Dec. 2009, 281, 678 babies were alive at birth discharge, excluding 
1,811 stillbirths and 777 babies who died during the birth admission.  In 2007, 2008 and 2009, 
the prevalence of VK prophylaxis was 95.9%, 96.3% and 96.7% for IM administration, 2.9%, 
2.5% and 2.3% for oral and 1.2%, 1.2% and 1.1% for no VK, respectively. Compared to 
neonates administered IM injections, those with oral or no VK were more likely to have older 
mothers without any medical conditions, who received antenatal care from a general practitioner 
or from a combination of antenatal care models, had spontaneous labour, an analgesia-free 
delivery, a normal vaginal delivery in a birth center or a planned homebirth, and less likely to 
have neonatal hepatitis B vaccine (Table 1). Neonates who were preterm births and breast-
feeding at discharge were significantly more likely to have received oral rather than IM VK.  
Compared to neonates who received IM injection, neonates who had ‘none’ recorded on the form 
for VK were more likely to be planned deliveries at a birth center or planned homebirth that 
resulted in a hospital admission and to be admitted to a neonatal or special care unit during their 
birth admission; however, there was no significant difference between term and preterm births. 
 
Discussion 
To our knowledge, this is the first study to examine maternal and infant characteristics by 
mode of VK prophylaxis. Findings reveal that in Australia, parental decision to use oral or no 
VK prophlaxis is aligned with attitudes and preferences for a natural birth without medical 
interventions.  This finding supports previous research on the health beliefs of parents with low 
uptake of other vaccines and suggests that IM prophylaxis of VK is unattractive to parents with 
concerns about the “medicalisation” of birth and the risks of the injection itself.6  The generation 
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of public debate and anxiety around IM prophylaxis of VK from scientific evidence is illustrated 
in other examples of reported associations, such as pertussis immunisation and encephalopathy 
of infancy, or MMR immunisation and autism, both of which have since been dismissed.1  
Of concern, neonates who were preterm births and those who were breast-fed at 
discharge were significantly more likely to have been administered VK orally compared to IM 
injection.  Limited fetal stores of VK at birth, especially in preterm infants, and the low VK 
content of human milk places these infants at increased risk for VKDB.1  Multiple oral doses are 
prescribed because a single dose only offers protection for approximately 4 weeks and infants 
exclusively breast-fed receive inadequate VK from breast milk.4  Neonates recorded as not 
receiving any VK represent a relatively small group (1%); however, the absolute number is not 
inconsequential (n=3,136).  Neonates in this group over-represented extremely ill babies who 
were admitted to a neonatal or special care unit and may have been administered VK later in 
treatment during their birth admission after the midwife had already been completed the MDC 
form. These neonates were more likely to have natural births without medical interventions and 
less likely to receive a hepatitis B vaccine, thus, it is possible that some missed out on VK 
prophlaxis because of parental safety concerns.  Of note, the hepatitis B immunisation of infants 
is offered universally in NSW.7  
While VKBD is a rare disease, the consequences are severe.1, 8  The Australian Pediatric 
Surveillance Unit (APSU) reported 6 confirmed cases of VKBD from 2007-2008, the majority of 
which were late onset VKDB.5 Of those with a late onset, more than half had liver disease.5 Most 
children with VKDB were found to have received insufficient or no VK at birth 5.  Two of three 
infants who died from VKDB were without liver disease and did not receive VK at birth.5  
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Implications of a change in the mode of VK administration in newborns (introduction of oral 
preparations) is currently being examined in Australia.4   
Our study does not have details on infants where the VK record was missing data.  
Subjects with blank entries represented a small percentage of cases (0.08%) and were excluded 
from analyses to avoid biasing results; however it would have been interesting to know whether 
missing cases related to parental choices, caregiver recommendations, or recording errors.  The 
study also has limited generalizability.  VK prophylaxis practices vary by country and results 
from this study may not pertain to other populations with different neonatal immunisation 
guidelines or parental preferences and knowledge of preventative practices.  Study strengths 
include the size and validity of the population database used.9  
A small proportion of the Australian public remains concerned about the safety of IM 
injection of VK to neonates.  It is impossible to give unequivocal reassurance on this point; 
current scientific evidence does not support an association between IM injection of VK and 
increased risk of cancer; however, it is not possible to exclude a small increased risk in 
leukaemia due to limitations of the data.4, 8   Oral prophylaxis is easy and non-invasive; however, 
parents need to be informed of the disadvantages of uncertain absorption which can be adversely 
affected by vomiting or regurgitation and the reliance on parental compliance to administer 
multiple doses in early infancy to ensure neonates have full protection from developing VKDB. 
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Table 1. Oral and no vitamin K prophylaxis compared with intramuscular (IM) injection in 
NSW Australia (2007-2009). 
 Proportions (%) Oral VK None VK 
 IM 
(n=263,555) 
Oral 
(n=7,023) 
None 
(n=3,136) 
Adjusted odds 
ratio  (95% CI) 
Adjusted odds ratio  
(95% CI) 
Maternal age, years 
<24 
25-34  
≥35  
 
16.8 
59.5 
23.8 
 
12.6 
58.0 
29.5 
 
13.5 
56.3 
30.2 
 
0.63 (0.58, 0.68) 
Reference 
1.44 (1.36, 1.52) 
 
1.05 (0.93, 1.19) 
Reference 
1.10 (1.00, 1.20) 
No. of previous pregnancies 
0 
1 
2 
≥3 
 
41.9 
33.7 
15.2 
9.2 
 
47.6 
31.6 
12.4 
8.4 
 
41.7 
30.5 
15.7 
12.2 
 
Reference 
0.74 (0.69, 0.78) 
0.59 (0.54, 0.63) 
0.58 (0.53, 0.64) 
 
Reference 
0.86 (0.78, 0.95) 
0.92 (0.81, 1.04) 
1.12 (0.97, 1.28) 
Smoking during pregnancy 12.4 10.2 8.7 0.82 (0.76, 0.89) 0.85 (0.74, 0.98) 
Maternal medical condition1 11.9 9.1 9.2 0.86 (0.79, 0.94) 0.95 (0.83, 1.09) 
Model for antenatal care 
Midwife only  
General practitioner only 
Hospital-based medical only 
Private obstetrician only 
More than one combination 
 
28.2 
8.7 
15.8 
33.0 
14.4 
 
35.2 
16.3 
12.0 
18.3 
18.3 
 
46.4 
7.8 
16.3 
12.7 
16.8 
 
Reference 
2.02 (1.88, 2.18) 
0.75 (0.69, 0.81) 
0.51 (0.47, 0.54) 
1.26 (1.17, 1.35) 
 
Reference 
1.31 (1.12, 1.52) 
0.90 (0.79, 1.01) 
0.52 (0.46, 0.59) 
1.14 (1.01, 1.28) 
Onset of labour 
Spontaneous 
Induced 
No labour 
 
56.9 
25.9 
17.2 
 
67.0 
20.7 
12.3 
 
73.6 
14.0 
12.4 
 
Reference 
0.85 (0.80, 0.91) 
0.85 (0.77, 0.94) 
 
Reference 
0.70 (0.63, 0.79) 
0.87 (0.74, 1.02) 
No analgesia during labour 32.3 38.3 49.7 1.06 (1.00, 1.12) 1.28 (1.16, 1.41) 
Type of delivery 
Normal vaginal 
Instrumental2 
Vaginal breech 
Caesarean section 
 
58.8 
11.2 
0.2 
29.9 
 
65.6 
9.5 
0.4 
24.5 
 
69.8 
6.0 
0.8 
23.4 
 
Reference 
0.83 (0.76, 0.91) 
1.21 (0.80, 1.83) 
0.92 (0.85, 1.00) 
 
Reference 
0.72 (0.61, 0.85) 
1.29 (0.80, 2.08) 
1.08 (0.94, 1.24) 
Baby's place of birth 
Hospital 
Birth Centre (BC) 
Planned homebirth (HB) 
Hospital admission (BC/HB) 
Born before arrival 
 
95.6 
2.7 
0.04 
1.2 
0.5 
 
88.4 
8.9 
0.8 
1.3 
0.6 
 
73.9 
11.4 
10.5 
2.9 
1.4 
 
Reference 
2.26 (2.06, 2.49) 
5.50 (3.88, 7.78) 
0.85 (0.69, 1.05) 
1.12 (0.82, 1.52) 
 
Reference 
2.02 (1.76, 2.33) 
23.52 (18.12, 30.53) 
1.45 (1.15, 1.84) 
1.82 (1.30, 2.57) 
Hepatitis B birth dose given 94.7 76.0 16.2 0.22 (0.21, 0.24) 0.01 (0.01, 0.02) 
Neonate health status3 
Term birth, not admitted to 
NIC3 
Preterm, admitted to NIC 
Term birth, admitted to NIC 
Preterm, not admitted to NIC 
 
84.7 
 
4.0 
9.6 
1.7 
 
82.0 
 
6.9 
8.6 
2.5 
 
74.5 
 
12.0 
12.2 
1.3 
 
Reference 
 
1.70 (1.54, 1.89) 
1.01 (0.92, 1.10) 
1.60 (1.37, 1.87) 
 
Reference 
 
1.56 (1.36, 1.80) 
1.52 (1.34, 1.72) 
0.93 (0.67, 1.30) 
Breastfeeding on discharge 84.6 86.9 83.3 1.09 (1.01, 1.17) 0.97 (0.86, 1.09) 
1Coded ‘yes’ if mother had any of the following conditions: diabetes, gestational diabetes, hypertension or 
preeclampsia. Coded ‘no’ if mother had none of the above reported conditions. 
2Instrumental: forceps or vacuum extraction. 
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3 NIC is an abbreviation for neonatal intensive care or special care unit and preterm birth was defined as 
gestational age <37 weeks.  
